Transitional Cell Carcinoma — Trials

Transitional Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

734 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 253
Recruiting: 125
Ph III recruiting: 17
Growth YoY: +47.5%
Industry share: 31%
Top sponsor: National Cancer Institute (NCI)
Termination share: 44%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (119)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05494411	Named Patient Program for Mitomycin for Pyelocalyceal Solution	available	—	—	UroGen Pharma Ltd.INDUSTRY	0	Sep 15, 2026	clinicaltrials
NCT06443944	An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG	available	—	—	CG Oncology, Inc.INDUSTRY	1	Sep 11, 2026	clinicaltrials